Browsing Tag
Nasdaq Global Select Market
4 posts
Is Parabilis Medicines’ $670m Nasdaq IPO a biotech comeback signal or a high-risk oncology wager?
Find out how Parabilis Medicines’ upsized Nasdaq IPO reshapes biotech financing, Regeneron validation and investor appetite for Helicon platform drugs now.
A $560m test for the diabetes device market as MiniMed prepares to trade on Nasdaq
MiniMed prices its IPO at $20 per share, raising $560M as Medtronic plc spins out its diabetes unit. Discover what the move means for the diabetes technology market.
Momentus Inc confirms reverse stock split in bid to maintain Nasdaq Global Select Market listing
Find out how Momentus Inc’s reverse stock split aims to protect its Nasdaq listing and reshape investor sentiment in the commercial space sector.
SEALSQ reaches $1bn market cap as Nasdaq Global Select uplisting boosts investor confidence
Find out how SEALSQ’s Nasdaq Global Select uplisting and $1 billion valuation are reshaping investor confidence in post-quantum semiconductor security.